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Abstract Evaluating early changes in cerebral metabo-
lism in hydrocephalus can help in the decision making and
the timing of surgical intervention. This study was aimed at
examining the tricarboxylic acid (TCA) cycle rate and
13C
label incorporation into neurotransmitter amino acids and
other compounds 2 weeks after rats were subjected to
kaolin-induced progressive hydrocephalus. In vivo and ex
vivo magnetic resonance spectroscopy (MRS), combined
with the infusion of [1,6-
13C]glucose, was used to monitor
the time courses of
13C label incorporation into the dif-
ferent carbon positions of glutamate in the forebrains of
rats with hydrocephalus as well as in those of controls.
Metabolic rates were determined by ﬁtting the measured
data into a one-compartment metabolic model. The TCA
cycle rate was 1.3 ± 0.2 lmoles/gram/minute in the con-
trols and 0.8 ± 0.4 lmoles/gram/minute in the acute
hydrocephalus group, the exchange rate between a-keto-
glutarate and glutamate was 4.1 ± 2.5 lmoles/gram/min-
ute in the controls and 2.7 ± 2.6 lmoles/gram/minute in
the hydrocephalus group calculated from in vivo MRS.
There were no statistically signiﬁcant differences between
these rates. Hydrocephalus caused a decrease in the
amounts of glutamate, alanine and taurine. In addition, the
concentration of the neuronal marker N-acetyl aspartate
was decreased.
13C Labelling of most amino acids derived
from [1,6-
13C]glucose was unchanged 2 weeks after
hydrocephalus induction. The only indication of astrocyte
impairment was the decreased
13C enrichment in glutamine
C-2. This study shows that hydrocephalus causes subtle but
signiﬁcant alterations in neuronal metabolism already early
in the course of the disease. These sub-lethal changes,
however, if maintained and if ongoing might explain the
delayed and programmed neuronal damage as seen in
chronic hydrocephalus.
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Introduction
In hydrocephalus the intracranial cerebrospinal ﬂuid (CSF)
volume is increased followed by compression of brain
tissue. Kaolin-induced hydrocephalus is an intensively
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in 1932 [1]. In this model kaolin is injected under micro-
scopic guidance into the cisterna magna resulting in a
sterile meningeal inﬂammation. This leads to an obstruc-
tion of the foramina of Luschka and Magendi and thus to
hydrocephalus and syringomyelia [2]. Clinical symptoms
of acute hydrocpehalus are evoked by an increase in
intracranial pressure and outﬂow resistance. Treatment of
chronic hydrocephalus is operative, but decision making
concerning the appropriate timing of surgical treatment is
difﬁcult. Despite enormous efforts in hydrocephalus
research, this issue is still not satisfactorily solved. Thus,
non-invasive techniques to assess development of hydro-
cephalus have to be established. A possible solution might
be to monitor changes in cerebral metabolism which has
been shown to take place in hydrocephalus [3]. In vivo
MRS can provide valuable information about cerebral
metabolites and tricarboxylic acid (TCA) cycle rates and
thus, such studies of the brain with hydrocephalus could be
of signiﬁcant clinical importance.
13C MRS has been employed extensively to study
cerebral metabolism and TCA cycle activity in animals
after the injection of
13C labelled substrates. Since
13C
labelled metabolites such as glutamate and aspartate are in
equilibrium with TCA cycle intermediates, the level of
labelling of these measured metabolites reﬂect TCA cycle
activity. The present study is the ﬁrst to describe the in vivo
TCA cycle rate in rats subjected to hydrocephalus.
Hydrocephalus was induced by kaolin-instillation into the
cisterna magna of Sprague–Dawley rats and 2 weeks later
[1,6-
13C]glucose was infused and in vivo MRI and
13C
MRS were preformed. The incorporation of
13C label from
[1,6-
13C]glucose into [4-
13C]- and [3-
13C]glutamate was
thus observed. The time courses of
13C label incorporation
into glutamate in the brains of rats with hydrocephalus as
well as in controls were ﬁtted using a one-compartment
metabolic model allowing non-invasive determination of
the neuronal TCA cycle rate and the exchange rate between
a-ketoglutarate and glutamate. Since most glutamate is
located in neurons [13], metabolic rates obtained using this
model primarily reﬂects neuronal metabolism. Thereafter,
labelling of different metabolites in the cortex was mea-
sured by ex vivo
13C MRS and amino acid concentrations
were determined using high performance liquid chroma-
tography (HPLC) of tissue extracts.
Experimental Procedures
Animals
All experimental procedures were approved by the Nor-
wegian Experimental Animal Board. Animals had free
access to water and food and were kept under standard
laboratory conditions (room temperature 22C, 66%
humidity, 12/12 h light/dark cycle). Five Sprague–Dawley
rats (2 months old, 200 g, Mollergaard Breeding Centre,
Copenhagen, Denmark) were anaesthetized with ketamine
(100 mg/kg, ketalar, Warner Lambert, Nordic AB, Solna,
Sweden) and medotomidinehydrochlorid (0.5 mg/kg,
Janssen-Cilag Ltd., Sollentuna, Sweden) and made hydro-
cephalic by microsurgical instillation of 0.1 ml kaolin
(4 g/ml 0.9% saline, NMD, Oslo, Norway) into the cisterna
magna. Five rats were sham-operated and served as con-
trols. Postoperatively, rats were kept one per cage at a
light–dark shift of 12 h and received water and food
ad libitum. In vivo MRS was performed in all animals, but
due to technical problems only 3 spectra of sufﬁcient signal
to noise ratio of the peaks in the
13C MR spectra were
obtained for each group. In addition, 4 rats were used to
determine the input function of glucose.
Determination of the Input Function of Glucose
The time courses of incorporation of labelling in [4-
13C]-
and [3-
13C]glutamate in the brain were ﬁtted into a one-
compartment metabolic model (see section below) which
yielded the rate of the TCA cycle and the exchange rate
between a-ketoglutarate and glutamate. The time courses
of incorporation of
13C labelling into glutamate C-4 and
C-3 depend on the kinetics of
13C labelling of glucose in
the blood. The latter time course is called the input function
and was determined by measuring the
13C enrichment of
glucose in blood during the infusion. Without knowledge
of the input function, the rate of
13C labelling of glutamate
cannot be interpreted, since it is not known how quickly the
13C labelled substrate enters the system. Since blood can-
not be drawn easily inside the magnet in rats with a small
blood volume, additional measurements were performed on
the bench using the same infusion protocol as for the MRS
experiment to determine the input function and to assess
arterial pH, pCO2, pO2, glucose and lactate. Four animals
were fasted for 18–20 h prior to the experiment; their
weight was 258 ± 4 g after fasting. Spontaneously
breathing animals were anesthetized with 3.5% isoﬂurane
in 30/70% O2/N2 using a small animal ventilator (Harvard
Apparatus, MA, USA) in a closed chamber. During surgery
and also later during glucose infusion the animals were
spontaneously breathing 2% isoﬂurane in 30/70% O2/N2
delivered though a face mask. Body temperature was
maintained using a feed-back controlled heating table
connected to a rectal probe. One catheter was introduced
into the right femoral vein, and one in the right femoral
artery. The insertion was sprayed with lidocain (10 mg/
doses) and closed, with the catheters emerging from the
middle and posterior end of the incision. Arterial blood
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123samples from the control animals were drawn 5 min before
the start of the intravenous glucose infusion, at the start of
the infusion and thereafter then 5, 10, 15, 30, 45, 60 and
80 min after the start of the infusion. Approximately
300 ll arterial blood was drawn at each time point. One
hundred micro liter was used for the measurement of pH,
plasma lactate and glucose as well as blood gasses using a
blood gas analyzer (Siemens RapidLab 1200, Siemens
Health Care, USA). Two hundred micro liter of blood was
transferred to an Eppendorf tube and centrifuged at
1,000 rpm for 5 min and at 4C. Plasma samples were
extracted with 1 ml ice-cold 7% perchloric acid and cen-
trifuged for 10 min at 4C and 4,000g. Each sample was
neutralized with 2 M KOH, centrifuged and lyophilized.
The lyophilized plasma samples were dissolved in 400 ll
D2O (99%, Cambridge Isotope Laboratories, Woburn,
Massachusetts, USA) and analyzed with high resolution
1H
MRS to determine the fractional
13C enrichment of glu-
cose.
1H NMR spectra were acquired on a Bruker DRX500
spectrometer 11.7T, (Bruker Biospin GmbH, Rheinstetten,
Germany) with the following acquisition parameters: 90
pulse angle, an acquisition time of 1.36 s and a relaxation
delay of 10 s, 512 scans were accumulated for each sam-
ple. Water suppression was achieved by applying a low-
power pre-saturation pulse at the water frequency. The
glucose peaks in the
1H spectra were quantiﬁed by inte-
gration in XWINNMR in relation to a known amount of
ethylene glycol added to the sample.
In Vivo Magnetic Resonance Protocol
In vivo
13C MRI and MRS were performed on hydro-
cephalus and sham-operated rats 2 weeks after surgery.
The rats were fasted 18–20 h before the experiment. On the
day of the experiment the rats with induced hydrocephalus
weighed 197 ± 25 g (n = 3) and the control group
weighed 300 ± 5g( n= 3). The spontaneously breathing
animals were anesthetized with 3.5% isoﬂurane (Baxter,
Norway) in 30/70% O2/N2 using a small animal ventilator
(Harvard Apparatus, MA, USA) in a closed chamber.
During surgery the animals were spontaneously breathing
2% isoﬂurane in 30/70% O2/N2 delivered though a face
mask. Body temperature was maintained using a feed-back
controlled heating blanket connected to a rectal probe. First
a catheter was introduced into the right femoral vein. The
insertion was sprayed with lidocain (10 mg/doses) (Astra-
Zeneca, Norway) and closed, with the catheter emerging
from the posterior end of the incision. Subsequently the
scalp was surgically removed to minimize lipid signal
contamination. The skull was sprayed with lidocain
(10 mg/doses) and a layer of plastic wrap was placed over
the skull to prevent desiccation. During in vivo MRI and
MRS core body temperature was maintained between 36.5
and 38C by placing the animals in prone position on a pad
heated with circulating water (Bruker Biospin, Ettlingen,
Germany).
In vivo MRI and MRS were performed on a 7 Tesla
Bruker Biospec 70/20 magnet (Bruker Biospin, Ettlingen,
Germany) operating at 75.50 MHz (
13C) and 300.30 MHz
(
1H) with a 72-mm volume coil for transmission and an
actively decoupled quadrature rat head surface coil (20-
mm) for receive-only. Water-cooled BGA-12 (400 mT/m)
gradients were used. Coronal gradient-echo images
(RARE-sequence with a RARE factor of 16) were acquired
with TR = 6,000 ms, TE = 71.85 ms, number of aver-
ages = 8. A total of 30 slices were acquired with
FOV = 5 9 5 cm and a matrix of 256 9 256. Total MRI
scan time was 12 min and 48 s.
To monitor cerebral
13C label incorporation into cortical
metabolites (glutamate) an infusion of 1 M [1,6-
13C] glu-
cose (99%
13C enriched, Cambridge Isotope Laboratories,
Woburn, Massachusetts, USA) was administered. An initial
bolus infusion of 105 mg/kg/min for 2 min was followed
by a steady-state infusion of 35 mg/kg/min. The total
length of the infusion was approximately 80 min. The in
vivo
13C MR spectra were acquired using a homemade
10 mm circular singular transmit/receive
13C surface coil,
whereas the 72-mm transmit volume coil was used for
1H
decoupling. Nuclear Overhauser effect (NOE) enhanced
1H
decoupled
13C MR spectra were obtained from a non-
localized volume. Waltz 16 was used for decoupling pro-
tons. Magnetic ﬁeld homogeneity was optimized by ﬁrst
and second order shims using FASTMAP [4] on a selected
voxel that included most of the cortical area detected by the
surface coil.
13C MR spectra were summed in batches of
256 averages; giving a temporal resolution of 6 min and
24 s.
13C MR spectra were acquired continuously
throughout the glucose infusion. Before the infusion of
labelled glucose a baseline spectrum was acquired for each
animal. This baseline spectrum was subtracted from each
post infusion spectrum in order to eliminate the broad lipid
signal in the spectral region of interest. The dimensions of
the coil were such as that the majority of signal was
acquired from the cortical tissue. The relative amount of
[4-
13C]glutamate and [3-
13C]glutamate at each time point
was quantiﬁed by using the signal to noise function in
XWINNMR. At the last time point the signal intensities
were set to the concentration of [4-
13C]glutamate and
[3-
13C]glutamate which was determined by ex vivo MRS
on the extracted tissue samples, see the below section.
Ex Vivo
13C MRS and HLPC Analysis of Brain Tissue
Samples
After the in vivo
13C MRS experiment the animals were
sacriﬁced by micro-wave ﬁxation, 4 kW, 2.2 s (Model
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The cortex was dissected, weighed and frozen at -80C.
The dissected cortical tissue was homogenized with an
ultrasound sonicator Vibra Cell sonicator (Model VCX
750, Sonics & Materials, Newtown, CT, USA) in ice-
cold 0.7% perchloric acid and thereafter centrifuged for
20 min at 4C and at 10,000g. Ten micro liter of
supernatant was stored at -20C for HPLC analysis. The
rest of the supernatant was transferred into a new tube,
neutralized with 1 M KOH and centrifuged for 20 min at
4C and at 10,000g. The supernatants were thereafter
lyophilized and dissolved in 400 llD 2O (99%, Cam-
bridge Isotope Laboratories, Woburn, Massachusetts,
USA) containing 0.1% ethylene glycol as an internal
reference signal and pH was adjusted to values between
6.8 and 7.0. Proton decoupled
13C MR spectra were
acquired on a 11.7T Bruker DRX500 spectrometer
(Bruker Biospin GmbH, Rheinstetten, Germany), and
relevant peaks in the
13C spectra were quantiﬁed by
integration in XWINNMR in relation to the known
amount of ethylene glycol added to the sample. The
following acquisition parameters were applied; 30 pulse
angle, acquisition time of 1.3 s and a relaxation delay of
2.5 s. The number of scans was typically 15,000. Some
spectra were also broad band decoupled only during
acquisition and accompanied by a relaxation delay
of 20 s, to achieve fully relaxed spectra without NOE.
From several sets of spectra, correction factors were
obtained and applied to the integrals of the individual
peaks.
The total amounts of glutamate, glutamine, GABA,
alanine and aspartate in the extracts were quantiﬁed by
HPLC analysis after derivatization with o-phthaldialdehyde
essentially as described by Geddes and Wood [5], using a
Hewlett Packard 1100 apparatus (Agilent, Palo Alto, CA,
USA).
Percent enrichment in the
13C labelled metabolites was
calculated from the following formula:
%   enrichment
¼
½x   13C metabolite   1:1%½metabolite  ðÞ   100
½metabolite 
[Metabolite] represents the total amount of a given
metabolite measured by HPLC. [X-
13C]metabolite rep-
resent the concentration of a
13C isotopomer of a given
metabolite measured by
13C MRS in ex vivo tissue
extracts. This calculation was done for each peak in
the ex vivo
13C spectrum obtained for each rat
individually.
A t test was thereafter used to compare the means of the
HPLC and ex vivo
13C MRS data (n = 5 in each group),
and the statistical signiﬁcance was set to P\0.05.
Metabolic Model
The time course of plasma glucose
13C enrichment and the
time courses for incorporation of
13C label into
[4-
13C]glutamate and [3-
13C]glutamate from the in vivo
MRS experiment were ﬁtted with a comprehensive math-
ematical metabolic model described in Henry et al. [6]. The
metabolic model consists of a set of differential equations
which can be solved numerically using SAAM II (The
SAAM institute, Seattle, WA). Since most glutamate is
located in neurons [13], metabolic ﬂuxes obtained using
this model primarily reﬂect neuronal metabolism. Fur-
thermore, the concentrations of glutamate, glutamine and
aspartate measured by HPLC were also ﬁtted into the
model. Based on literature values the concentration of
oxaloacetate was assumed to be 1 lmol/g and that of
a-ketoglutarate was assumed to be 0.5 lmol/g in brain
tissue [7]. In the one-compartment model used there were
four unknown parameters; (1) a rate constant describing the
neuronal TCA cycle (VTCA) (2) the exchange rate between
a-ketoglutarate and glutamate (VX) (3) the rate constant
describing the dilution of labelled
13C lactate through
exchange with unlabelled lactate (VDIL) and (4) a dilution
ﬂux to account for loss of
13C-labelled glutamine through
exchange with unlabelled glutamine (VEFF)[ 6]. Further-
more, the model described in Henry et al. [6] assumes that
VGLN = 0.41 9 VTCA based on previous studies [7] and
since [1,6-
13C]glucose was infused the rate of glycolysis
VGLY was assumed to be the same as VTCA. Each animal
was modelled individually and mean values of the rate of
the neuronal TCA cycle and the exchange rate between
a-ketoglutarate and glutamate were then calculated for
each group. The dilution ﬂux to account for loss of
13C-labelled glutamine through exchange with unlabelled
glutamine could not be determined with accuracy for the
animals in the hydrocephalus group, and the rate constant
describing the dilution of labelled
13C lactate through
exchange with unlabelled lactate could not be determined
at all since this parameter reached the lowest limit con-
straint in the model which was 0.01. A non-parametric
Mann–Whitney test was thereafter applied to compare the
means, and the statistical signiﬁcance was set to P\0.05.
Results
All the rats subjected to kaolin injection were indeed
hydrocephalic as evidenced by ventriculomegaly involving
all ventricles and compression of cortical tissue (Fig. 1).
The bench experiment (n = 4, values are mean ± SD)
showed that the pH (7.35 ± 0.007), pO2 (31.3 ± 2.1 kPa)
and pCO2 (5.17 ± 0.43 kPa) were all at normal values
throughout the glucose infusion. Glucose concentration
1804 Neurochem Res (2011) 36:1801–1808
123rose from 5.8 ± 1.0 mmol/l at the start of the infusion to
36.5 ± 2.6 mmol/l at the end of the infusion, i.e. after
80 min. The concentration of plasma lactate was measured
to be 1.00 ± 0.04 mmol/l prior to the infusion and rose to
3.31 ± 0.51 mmol/l during the infusion.
The incorporation of
13C label into [4-
13C]glutamate and
[3-
13C]glutamate in the brain during glucose infusion is
shown in Fig. 2. As seen from the ﬁgure this incorporation
was lower in the hydrocephalus group as compared with the
control group. These time courses were ﬁtted with a one-
compartment model to determine the rate constant
describing the neuronal TCA cycle and the exchange rate
between a-ketoglutarate and glutamate, which are shown in
Table 1. The dilution ﬂux to account for loss of
13C-labelled
glutamine through exchange with unlabelled glutamine was
0.49 ± 0.02 lmoles/gram/minute in the control group, but
could not be determined in the hydrocephalus animals since
the standard deviation of the mean was larger than the mean
value itself. The rate constant describing the dilution of
labelled
13C lactate through exchange with unlabelled lac-
tate hit lower limit.
Oedema was assessed by comparing wet weight tissue
sample before extraction and the freeze dried pellet after
extraction and the ratio between them was 5.19 ± 0.15 for
controls and 5.61 ± 0.43 for the hydrocephalus group
(P = 0.075). Thus, there might be a slight accumulation of
water in the tissue of the animals with hydrocephalus.
Table 2 gives the concentration of metabolites that were
measured in the cortical tissue samples at the end of the
experiment corrected for wet weight. The contents of
glutamate, taurine, alanine and N-acetyl aspartate (NAA)
were decreased in the brains of the animals with hydro-
cephalus compared with the control group when corrected
for wet weight.
The content of
13C labelled metabolites and the %-
13C
enrichment (for calculation see materials and methods)
were very similar in most metabolites except for glutamine,
where both percent enrichment (28 ± 5% for controls and
22 ± 4% for hydrocephalus rats, P = 0.05) and amount of
label (1.65 ± 0.28 lmol/gram for controls and 1.17 ±
0.32 for hydrocephalus rats P = 0.03) were decreased in
the C-2 position.
Discussion
Several studies have used
31P,
1H and ex vivo
13C MRS to
study hydrocephalus and they all provide evidence for both
a disturbance of cerebral energy metabolism and neuronal
Fig. 1 Coronal T2-weighted MR images of controls and rats with
acute hydrocephalus 2 weeks after kaolin treatment are shown
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Fig. 2 Incorporation
13C into [4-
13C]glutamate (black triangles) and
[3-
13C]glutamate (open squares) for the control group and the
hydrocephalus group (lmol/gram/min). The error bars at each
experimental point denotes the SEM of three individual animals in
each group. The best ﬁts of the metabolic model to the data are shown
as continuous lines and the values of the rate of the neuronal TCA
cycle and the exchange rate between a-ketoglutarate and glutamate-
corresponds to the best ﬁt. These metabolic rates are given in Tabel 1
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123and/or myelin dysfunction [8–10]. The current study is the
ﬁrst one in which cerebral metabolism has been investi-
gated using in vivo
13C MRS in a rodent model of
hydrocephalus. This allows the assessment of the TCA
cycle rate based on measurements of
13C labelling time
courses in individual animals. Thus, the number of animals
used is reduced in contrast to metabolic rate determination
using ex vivo
13C MRS. Despite the poorer resolution in
spectra obtained using in vivo MRS, uncertainties in the
measurements related to post mortem changes and possible
errors in the extraction procedures are avoided.
The rate of the neuronal TCA cycle was not signiﬁcantly
different in the rats with hydrocephalus compared to the
control group in the present study. This is in line with
results obtained in an ex vivo
13C MRS study, where no
differences were found in
13C incorporation in glutamate,
glutamine, GABA and aspartate [11]. The fact that there
were no signiﬁcant differences in the rate of the neuronal
TCA cycle and the exchange rate between a-ketoglutarate
and glutamate between the groups indicates that the rats
with hydrocephalus were indeed able to maintain normal
TCA cycle metabolism. However, due to the small number
of animals in each group, only large differences in
metabolism will be detected. Also glycolysis appears to be
unchanged, since lactate levels were similar in the two
groups, in agreement with a previous study [3].
Subtle alterations in neuronal metabolism were detected
in rats with hydrocephalus compared with controls in the
present study. NAA is a neuronal marker [12], and most
glutamate is located in neurons [13]. Concentrations of
both these metabolite were decreased in cortex of rats with
hydrocephalus compared to those in control rats, pointing
to decreased neuronal function in the early stage (acute
phase) of hydrocephalus. A similar decrease in glutamate
level in rats 2 weeks after hydrocephalus induction was
observed by Kondziella et al. 2009 [3] using in vivo
1H
MRS. However, Kondziella et al. 2002 [14] analyzed
metabolites in the entire cerebrum at 2 weeks after
hydrocephalus induction and found no such difference.
Thus, it can be hypothesized that the largest changes in
glutamate concentration take place in the cortex, as both
the most recent studies analyzed cortical tissue and not the
entire brain. While the NAA level was decreased in the
present study, Kondziella et al. 2003 and 2009 [3, 11]
reported unchanged levels 2 weeks after kaolin induced
hydrocephalus. A similar discrepancy was obtained with
alanine, which was decreased in the present study, but not
in the aforementioned publications. This might point to
slight variations in the induction and possibly severity of
the kaolin model of hydrocephalus. Indeed results from
1H
MRS of brain extracts from Texas rats with hydrocephalus,
a genetic model of neonatal hydrocephalus due to aqueduct
stenosis with onset in late gestation, revealed a decrease in
many metabolites (about 50% reduction in glutamine,
glutamate, aspartate, creatinine, NAA, taurine and alanine)
compared to controls [15–17], pointing to marked differ-
ences on metabolites in different hydrocephalus models.
The present study provides important translational evi-
dence for an understanding of long-term sequels in chronic
hydrocephalus. It offers evidence to the fact that hydro-
cephaluscauses subtle butsigniﬁcant alterations in neuronal
Table 1 Values of of the rate of the neuronal TCA cycle and the exchange rate between a-ketoglutarate and glutamate derived from the ﬁt of the
experimental data with the metabolic model
Control (n = 3) Hydrocephalus (n = 3) P-value
Rate of neuronal TCA cycle 1.3 ± 0.2 0.8 ± 0.4 0.275
Exchange rate between a-ketoglutarate and glutamate 4.1 ± 2.5 2.7 ± 2.6 0.513
All results are expressed as mean ± standard deviation (lmoles/gram/minute).of 3 control animals and 3 rats with induced hydrocephalus.
Statistical differences between the two groups were analyzed using non-parametric Mann–Whitney test
* The level of signiﬁcance was set at P\0.05
Tabel 2 The amount of metabolites in the brain tissue of hydro-
cephalus animals and controls
Control
(n = 5)
Hydrocephalus
(n = 5)
P-value
Glutathione 1.12 ± 0.16 1.02 ± 0.20 0.89
Aspartate 1.93 ± 0.20 1.69 ± 0.17 0.11
Glutamate 9.20 ± 0.50 7.86 ± 0.97* 0.03
Glutamine 5.90 ± 0.61 5.5 ± 0.51 0.15
GABA 0.96 ± 0.18 0.88 ± 0.04 0.33
Taurine 5.29 ± 0.63 4.54 ± 0.33* 0.04
Alanine 0.93 ± 0.07 0.69 ± 0.15* 0.02
NAA 11.73 ± 1.03 9.41 ± 1.76* 0.03
Myo-inositol 4.13 ± 0.55 4.12 ± 1.29 0.99
Lactate 4.58 ± 1.46 3.73 ± 1.80 0.43
All results are expressed as mean ± standard deviation of 5 control
animals and 5 rats with hydrocephalus. All concentrations were cor-
rected for wet weight (lmol/g tissue). Statistical differences between
the two groups were analyzed using unpaired two-tailed Student’s
t test
* The level of signiﬁcance was set at P\0.05
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123metabolism already early in the course of the disease. These
sub-lethal changes, however, if maintained and if ongoing
might explain the delayed and programmed neuronal dam-
age as seen in chronic hydrocephalus.
Furthermore, in the present study there is indication of
reduction also in astrocyte metabolism, since there was a
decrease in labelling and %
13C enrichment in the C-2
position of glutamine. This position is labelled by repeated
turns in the TCA cycle with the same intensity as C-3 and
by pyruvate carboxylase, an astrocyte speciﬁc enzyme [18,
19]. Since only C-2 was affected and not C-3, the pyruvate
carboxylase activity appeared to be slightly decreased in
the hydrocephalus group. This is in line with a decrease in
astrocyte metabolism observed at 4 weeks after hydro-
cephalus induction using ex vivo MRS [11]. However, at
6 weeks (chronic hydrocephalus) astrocyte metabolism had
returned to controls levels [11].
Ventriculomegaly and brain tissue compression was
conﬁrmed with MRI of rats with hydrocephalus which was
in line with previous results [3, 9]. Considerable oedema
has been detected 4 weeks after kaoline injection [14].
However, at 2 weeks after kaoline injection only a ten-
dency towards elevated tissue water content was seen in the
current study, but this did not reach statistical signiﬁcance.
An additional indication of disturbed tissue water content
was the ﬁnding of altered levels of the osmolyte taurine.
However, the amount of taurine was signiﬁcantly
decreased in the hydrocephalus group compared with
controls, similar to the ﬁndings in Kondziella et al. 2002
[14]. Altered taurine levels can be used to control osmolyte
balance in the event of changes in water content.
In conclusion, the present results show that in acute
experimental hydrocephalus there is slightly reduced neu-
ronal and astrocytic metabolism, but still the hydrocephalic
brain is able to maintain its overall metabolism as mea-
sured by the rate of the neuronal TCA cycle. This supports
the hypothesis that in hydrocephalus disturbance of CSF
dynamics is not the only pathophysiologic factor but that
metabolic impairment is also of signiﬁcance [20]. Sublethal
deterioration of brain function in the acute course of
hydrocephalus has been shown by experimental and clini-
cal studies of blood ﬂow [21] and the present study adds
metabolic evidence to it. Possibly, modern metabolic
spectroscopy might be used in the future as a diagnostic
tool in human hydrocephalus and assist decision making on
treatment.
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